These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Current Management of Disseminated Germ Cell Tumors. Lavoie JM; Kollmannsberger CK Urol Clin North Am; 2019 Aug; 46(3):377-388. PubMed ID: 31277732 [TBL] [Abstract][Full Text] [Related]
3. Lens Culinaris Agglutinin-reactive Fraction of Alpha-fetoprotein as a Tumor Marker in a Patient With Nonseminomatous Germ Cell Tumor With Normal Alpha-fetoprotein Level. Sugiyama H; Takeshita H; Tachibana K; Hiranuma S; Takagi D; Kagawa M; Yano A; Okada Y; Morozumi M; Kawakami S Clin Genitourin Cancer; 2020 Jun; 18(3):e309-e311. PubMed ID: 31926880 [No Abstract] [Full Text] [Related]
4. Poor-prognosis germ cell tumors: we have not yet crossed the finish line. Vaughn DJ; Stadtmauer EA J Clin Oncol; 2007 Jan; 25(3):239-40. PubMed ID: 17235039 [No Abstract] [Full Text] [Related]
5. [Chemotherapy of disseminated germ cell tumors of the testis]. Tiuliandin SA Sov Med; 1987; (11):78-81. PubMed ID: 2451298 [No Abstract] [Full Text] [Related]
6. Evidence-based treatment for advanced germ cell tumor of the testis with a case illustration. Lin CK; Liu HT J Chin Med Assoc; 2010 Jul; 73(7):343-52. PubMed ID: 20688298 [TBL] [Abstract][Full Text] [Related]
7. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363 [TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3). Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007 [TBL] [Abstract][Full Text] [Related]
9. Disease Characteristics and Treatment Outcome of Testicular Germ Cell Tumors Treated with Platinum-Based Regimens. Sattar A; Masood M; Nisar H; Fatima I; Shahid AB J Coll Physicians Surg Pak; 2018 Apr; 28(4):292-296. PubMed ID: 29615170 [TBL] [Abstract][Full Text] [Related]
10. Treatment results of stage III germinal testicular tumors. Akdaş A; Kirkali Z; Altuğ U; Ilker Y Turk J Pediatr; 1984; 26(1-4):301-6. PubMed ID: 6085662 [No Abstract] [Full Text] [Related]
11. [Chemotherapeutic treatment regimens for germinal testicular tumors]. Hofmann W; Langkopf B; Heinrichs HJ; Rebmann U Z Urol Nephrol; 1983 Nov; 76(11):741-50. PubMed ID: 6320553 [No Abstract] [Full Text] [Related]
12. Selected use of aggressive adjuvant chemotherapy in resected stage II nonseminomatous germ cell tumors of the testis. Pizzocaro G Prog Clin Biol Res; 1985; 203():585-90. PubMed ID: 2421344 [No Abstract] [Full Text] [Related]
13. Recent developments in germ cell tumors of the testes. Tummala MK; Hussain A Curr Opin Oncol; 2008 May; 20(3):287-93. PubMed ID: 18391628 [TBL] [Abstract][Full Text] [Related]
14. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumors (NSGCT). Huddart RA; Purkalne G; Ann Oncol; 2005; 16 Suppl 1():i37-9. PubMed ID: 15888747 [No Abstract] [Full Text] [Related]
15. Predictive factors for the histologic nature of residual tumor mass after chemotherapy in patients with advanced testicular cancer. Matsuyama H; Yamamoto N; Sakatoku J; Suga A; Hayashida S; Kamiryo Y; Nagata K; Naito K Urology; 1994 Sep; 44(3):392-8; discussion 398-9. PubMed ID: 8073552 [TBL] [Abstract][Full Text] [Related]